Results 71 to 80 of about 45,696 (262)

Ceftazidime/Avibactam: Who Says You Can’t Teach an Old Drug New Tricks?

Journal of Pharmacy & Pharmaceutical Sciences, 2016
Purpose: Gram-negative resistance continues to rise with treatment options becoming more limited. Ceftazidime/avibactam was recently approved in the United States and Europe, which combines an established third-generation cephalosporin with a new, unique,
Katie E. Barber, Jessica K. Ortwine, Ronda L Akins   +2 more
doaj   +1 more source

ARC in Critical Ill OLT Recipients: True Prevalence, Risk Factors, and Impact on Early Aggressive PK/PD Target Non‐Attainment of CI Beta‐Lactam Therapy for Posttransplant Gram‐Negative Infections

Transplant Infectious Disease, EarlyView.
Augmented renal clearance (ARC) represents a quite prevalent condition among critical orthotopic liver transplant recipients (23.2%). ARC is associated with different demographics and clinical features and significantly affects the attainment of aggressive beta‐lactams pharmacokinetic/pharmacodynamic targets despite the administration of standard ...
Milo Gatti, Riccardo De Paola, Matteo Rinaldi, Cristiana Laici, Antonio Siniscalchi, Pierluigi Viale, Federico Pea   +6 more
wiley   +1 more source

First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate [PDF]

, 2015
Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella ...
Humphries, Romney M, Yang, Shangxin, Hemarajata, Peera, Gregson, Aric, Hindler, Janet A, Ward, Kevin W, Miller, Shelley A   +6 more
core   +1 more source

Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies

Microbiology Spectrum, 2022
The evolution of bacterial antibiotic resistance is exhausting the list of currently used antibiotics and endangers those in the pipeline. The combination of antibiotics is a promising strategy that may suppress resistance development and/or achieve ...
Congjuan Xu, Xiaoya Wei, Yongxin Jin, Fang Bai, Zhihui Cheng, Shuiping Chen, Xiaolei Pan, Weihui Wu   +7 more
doaj   +1 more source

Tissue and Serum Concentrations of Time‐Dependent Antibiotics in Infected Diabetic Foot Ulcers by Bolus or Continuous Administration: The Randomised DFIATIM Trial

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 5, July 2026.
ABSTRACT Aims The clinical effectiveness of antibiotic (ATB) therapy in patients with infected diabetic foot ulcers (iDFUs) depends on achieving sufficient ATB concentrations in both serum and peripheral tissues. This study evaluated the availability and bactericidal activity of the time‐dependent ATBs—ceftazidime (CTZ) and amoxicillin/clavulanate (AMC)
Radka Jarošíková, Dominika Sojáková, Simona Antalová, Petr Tůma, Jan Polák, Michal Dubský, Andrea Němcová, Veronika Wosková, Pavol Beca, Istvan Modos, Jan Mareš, Jakub Mrázek, Chahrazed Mekadim, Markéta Skružná, Vladimíra Fejfarová   +14 more
wiley   +1 more source

Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: Experience from a national registry study

, 2021
Background: Infections caused by KPC-producing Klebsiella pneumoniae (Kp) are associated with high mortality. Therefore, new treatment options are urgently required.
Giamarellou, H., Symbardi, S., Filiou, E., Adamis, G., Basoulis, D., Mouloudi, E., Karaiskos, I., ikaraiskos@hygeia.gr, Akinosoglou, K., Gkoufa, A., Masgala, A., Petraki, M., Stefos, A., Chrysos, G., Daikos, G.L., Galani, L., Papadimitriou, E., Poulakou, G., Routsi, C., Galani, I., Arvaniti, K., Karaiskos I., ikaraiskos@hygeia.gr, Daikos G.L., Gkoufa A., Adamis G., Stefos A., Symbardi S., Chrysos G., Filiou E., Basoulis D., Mouloudi E., Galani L., Akinosoglou K., Arvaniti K., Masgala A., Petraki M., Papadimitriou E., Galani I., Poulakou G., Routsi C., Giamarellou H.   +20 more
core   +1 more source

Multiple Novel Ceftazidime-Avibactam-Resistant Variants of blaKPC-2-Positive Klebsiella pneumoniae in Two Patients

Microbiology Spectrum, 2022
As the first-line antimicrobial agent for the infection caused by carbapenem-resistant Enterobacterales, ceftazidime-avibactam develops drug resistance during its ever-growing clinical use.
Qingyu Shi, Renru Han, Yan Guo, Yang Yang, Shi Wu, Li Ding, Rong Zhang, Dandan Yin, Fupin Hu   +8 more
doaj   +1 more source

Antibiotic‐Impregnated Calcium Sulfate Beads for Local Therapy of Severe Skull Base Osteomyelitis

Clinical Case Reports, Volume 14, Issue 6, June 2026.
Novel Local Therapy of Severe Skull Base Osteomyelitis. ABSTRACT We report on a patient with severe progressive osteomyelitis of the lateral skull base, despite targeted long‐term antibiotic therapy. Successful treatment and recovery of the facial nerve palsy were achieved through additional surgical debridement and insertion of synthetic calcium ...
Stefan Lyutenski, Aviva Henze, Paul James, Marc Bloching   +3 more
wiley   +1 more source

Ceftazidime-Avibactam for Carbapenem-Resistant Gram-Negative Bacteria Infections: A Real-World Experience in the ICU

, 2023
Jiaxin Yu,1,2 Wei Zuo,1,2 Hongwei Fan,1,3 Jiayu Wu,1,2 Luyao Qiao,1,2,4 Benyu Yang,1,2,5 Wenxi Li,1,2,5 Yang Yang,1,2,* Bo Zhang1,2,* 1Department of Pharmacy, Peking Union Medical College Hospital, Beijing, People’s Republic of China; 2State Key ...
Zuo W, Li W, Wu J, Fan H, Yang Y, Yang B, Yu J, Zhang B, Qiao L   +8 more
core  

Klebsiella pneumoniae Mutants Resistant to Ceftazidime-Avibactam Plus Aztreonam, Imipenem-Relebactam, Meropenem-Vaborbactam, and Cefepime-Taniborbactam [PDF]

, 2022
We show that a previously described Klebsiella pneumoniae variant that is resistant to ceftazidime-avibactam plus meropenem-vaborbactam, has a ramR plus ompK36 mutation, and produces the V239G variant KPC-3 (V240G per the standard numbering system ...
Avison, Matthew B, Satapoomin, Aim, Dulyayangkul, Punyawee   +2 more
core   +1 more source